Excellent clinical results for Kite, shares notch record growth: +12%

Kite Pharma announced to the Annual Meeting of American Society of Hematology the preliminary results of its ZUMA-1 clinical trial, designed to assess axicabtagene ciloleucel (KTE-C19) in patients with non-Hodgkin lymphoma. The data were positive: indeed, they demonstrated that 82% of treated patients (in a sample of 101) showed cancer size reduction (ORR). However, what really convinced scientists was that only 2% of patients showed a cancer relapse after 6 months, which proves that the drug has a long-lasting effect – the lack of evidences about a long-lasting effect was a concern for many analysts. Kite’s shares rose 25% soon after the announcement. (Source Kite)